KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic Results From a Phase 1 Single Ascending Dose Study

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.118
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis

New England Journal of Medicine
Medicine
2017English

Treatment of Hereditary Angioedema With Plasma-Derived C1 Inhibitor

Therapeutics and Clinical Risk Management
2008English

Bilateral Angioedema of Eye With Single Dose of Cetirizine

International Journal of Basic and Clinical Pharmacology
2015English

Pharmacokinetics of Fentanyl Sublingual Spray in Opioid-Naïve Participants: Results of a Phase 1, Multiple Ascending Dose Study

Clinical Drug Investigation
MedicinePharmacology
2018English

Dose Proportionality and Pharmacokinetics Of carvedilol Sustained-Release Formulation: A single Dose-Ascending 10-Sequence Incomplete Block Study

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2015English

Single-Dose Botulinum Toxin Type a Compared With Repeated-Dose for Treatment of Trigeminal Neuralgia: A Pilot Study

Journal of Headache and Pain
MedicineNeurologyAnesthesiologyPain Medicine
2017English

Pharmacokinetic Evaluation of a Single Intramuscular High Dose Versus an Oral Long-Term Supplementation of Cholecalciferol

PLoS ONE
Multidisciplinary
2017English

Results of Single and Repeat Dose Studies of the Oral Matrix Metalloproteinase Inhibitor Marimastat in Healthy Male Volunteers

British Journal of Clinical Pharmacology
Pharmacology
1998English

Single-Dose Treatment of Gonorrhœa

The Lancet
Medicine
1972English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy